江苏康宁杰瑞生物制药有限公司
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
IND Application for Phase III Clinical Study of Anti-HER2 Bispecific Antibody KN026 was Officially Accepted by CDE 2021-10-21 10:31
Alphamab Oncology Completed Enrollment in the First Pivotal Phase III Clinical Study of the Bispecific Antibody KN046 2021-10-18 10:19
Alphamab Oncology Reports 2021 Interim Results and Business Highlights 2021-08-30 10:51
Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China 2021-08-24 15:08
Subcutaneously Injected PD-L1 Antibody Envafolimab (KN035) Obtained Its Second Orphan Drug Designation From The U.S. FDA 2021-06-30 08:55
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Plus Paclitaxel/Cisplatin for the First-line Treatment of ESCC at ASCO 2021 2021-06-07 10:11
Alphamab Oncology Presents Phase 2 Clinical Data on KN046 Combined with Chemotherapy for the Treatment of Advanced NSCLC at ASCO 2021 2021-06-07 10:10
Poster Highlighting Clinical Data of KN046 Plus Nab-Paclitaxel/Gemcitabine as First-Line Treatment for Pancreatic Cancer Is Presented at ASCO 2021 2021-06-07 09:53
Poster to Highlight ENVASARC Pivotal Trial of Envafolimab (KN035) will be presented at the 2021 ASCO Annual Meeting 2021-05-24 08:54
Alphamab Oncology to Present Multiple Clinical Research Data at the 2021 American Society of Clinical Oncology Annual Meeting (ASCO 2021) 2021-05-20 09:34
Alphamab announced PD-L1/CTLA-4 bispecific antibody KN046 will enter new Phase II clinical trial in combination with Pfizer's Inlyta® (axitinib) 2021-04-29 08:00
Alphamab Oncology Presented Clinical Data of KN046 Combined with Nab-paclitaxel in the Treatment of mTNBC at AACR 2021 2021-04-13 08:15
Alphamab Oncology Reports Full Year 2020 Financial Results and Business Highlights 2021-03-23 23:08
Alphamab Received U.S. FDA IND Clearance to Initiate A Phase II Pivotal Clinical Trial of KN046 (KN046-205,ENREACH-Thymic) in the U.S. 2021-03-09 20:00
Alphamab Oncology announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to KN046 for the treatment of thymic epithelial tumor 2020-09-03 23:46
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody 2020-06-10 08:40
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer 2020-06-09 10:10
Alphamab Oncology, Simcere and 3D Medicines Announce Partnership to Develop and Commercialize Subcutaneous Injectable anti-PD-L1 Antibody for Oncology Indications in Mainland China 2020-03-30 19:00
Alphamab Oncology Announces Clinical Supply Collaboration with Pfizer on KN026 in Combination with Ibrance(R) (palbociclib) 2020-03-27 19:00
Alphamab Oncology Announces Completion of US$60 Million Series B Financing 2019-05-28 19:02
1 2 3 4